1. Home
  2. HMC vs NTRA Comparison

HMC vs NTRA Comparison

Compare HMC & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Honda Motor Company Ltd.

HMC

Honda Motor Company Ltd.

HOLD

Current Price

$26.44

Market Cap

34.0B

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$212.26

Market Cap

29.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HMC
NTRA
Founded
1946
2003
Country
Japan
United States
Employees
215320
N/A
Industry
Auto Manufacturing
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.0B
29.1B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
HMC
NTRA
Price
$26.44
$212.26
Analyst Decision
Hold
Strong Buy
Analyst Count
1
15
Target Price
N/A
$259.07
AVG Volume (30 Days)
2.1M
1.3M
Earning Date
05-13-2026
05-07-2026
Dividend Yield
4.45%
N/A
EPS Growth
N/A
0.65
EPS
N/A
N/A
Revenue
N/A
$210,939,000.00
Revenue This Year
N/A
$18.08
Revenue Next Year
$4.36
$19.65
P/E Ratio
$40.40
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.25
$131.81
52 Week High
$34.89
$256.36

Technical Indicators

Market Signals
Indicator
HMC
NTRA
Relative Strength Index (RSI) 51.89 51.37
Support Level $26.09 $186.96
Resistance Level $26.66 $222.53
Average True Range (ATR) 0.44 10.51
MACD -0.08 0.34
Stochastic Oscillator 17.55 51.46

Price Performance

Historical Comparison
HMC
NTRA

About HMC Honda Motor Company Ltd.

Incorporated in 1948, Honda Motor was originally a motorcycle manufacturer. Today, the firm makes automobiles, motorcycles, and power products such as boat engines, generators, and lawnmowers. Including joint ventures, Honda sold 3.4 million light vehicles and 22.1 million motorcycles in fiscal 2026, and consolidated sales were JPY 21.8 trillion. Automobiles constitute 64% of revenue and motorcycles 18%, with the rest split between power products and financial services. Honda also makes robots and private jets.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: